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The phosphatidylinositol 3-kinase signal transduction pathway
members are often activated in tumor samples from patients
with non-Hodgkin’s lymphoma (NHL). Everolimus is an oral
agent that targets the raptor mammalian target of rapamycin
(mTORC1). The goal of this trial was to learn the antitumor
activity and toxicity of single-agent everolimus in patients with
relapsed/refractory aggressive NHL. Patients received ever-
olimus 10mg PO daily. Response was assessed after two and
six cycles, and then every three cycles until progression. A total
of 77 patients with a median age of 70 years were enrolled.
Patients had received a median of three previous therapies and
32% had undergone previous transplant. The overall response
rate (ORR) was 30% (95% conﬁdence interval: 20–41%), with
20 patients achieving a partial remission and 3 a complete
remission unconﬁrmed. The ORR in diffuse large B cell was
30% (14/47), 32% (6/19) in mantle cell and 38% (3/8) in follicular
grade 3. The median duration of response was 5.7 months.
Grade 3 or 4 anemia, neutropenia and thrombocytopenia
occurred in 14, 18 and 38% of patients, respectively. Everolimus
has single-agent activity in relapsed/refractory aggressive
NHL and provides proof-of-concept that targeting the mTOR
pathway is clinically relevant.
Leukemia (2011) 25, 341–347; doi:10.1038/leu.2010.226;
published online 7 December 2010
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Introduction
Patients with non-Hodgkin’s lymphoma (NHL) are highly
treatable and often curable. However, up to 40% of patients
with relapsed diffuse large B-cell NHL (DLBCL) die because
of their disease;
1 mantle cell lymphoma (MCL) is still not
predictably curable,
2,3 and there is substantial need to develop
new treatments for transformed lymphoma.
4 The PI3K/Akt/
mTOR pathway is a key growth and survival pathway for cancer
cells.
5–7 The mammalian target of rapamycin (mTOR) kinase, a
key member of the pathway, is a 289-kDa serine–threonine
kinase that exists in mutually exclusive complexes referred to as
mTORC1 and mTORC2.
8 Each complex has several compo-
nents, one of which is mTOR, the catalytic subunit. The key
mTORC1 components are regulatory-associated protein of
mTOR and mammalian lethal with Sec13 protein 8. mTORC1
positively regulates cell growth and proliferation, and has been
characterized as rapamycin sensitive. The components unique
to mTORC2 are rapamycin-insensitive companion of mTOR and
mammalian stress-activated protein kinase-interacting protein.
mTORC2 regulates Akt signaling and is characterized as the
rapamycin-insensitive complex.
Rapamycin (sirolimus)
9 is the parent drug of the class of
mTOR inhibitors that target mTORC1. The rapamycin analogs
temsirolimus and everolimus are now approved by the
United States Food and Drug Administration for renal cell
carcinoma.
10,11 These agents have demonstrated activity
against lymphoma cells both in vitro
12 and in vivo. For example,
single-agent temsirolimus has shown an overall response rate
(ORR) of B40% with a median duration of response (DR)
and time to progression of 6 months in two trials for relapsed
MCL.
13,14 A randomized phase III trial in relapsed MCL
demonstrated a higher ORR with temsirolimus compared with
standard chemotherapy, although the ORR in that trial was
only 22%.
15 A phase I trial of everolimus in hematological
malignancies demonstrated the safety of everolimus at a dose
of 10mg daily.
16 We have demonstrated safety and efﬁcacy of




18 and relapsed Hodgkin’s lymphoma.
19
Based on this preclinical work and the excellent toxicity
proﬁle of everolimus in previous studies, we performed a phase
II clinical trial of single-agent everolimus in patients with
relapsed aggressive NHL that had failed standard therapy.
Materials and methods
Laboratory experimental methods
To demonstrate that the everolimus used in this clinical trial
indeed did target the mTOR pathway in aggressive NHL, we
tested everolimus in vitro using the MCL cell lines Jeko1, Mino
and Granta. These were obtained from the American Type
Culture Collection (ATCC, Manassas, VA, USA) and grown in
RPMI-1640 with 10% fetal bovine serum. The DLBCL cell lines,
SUDHL6 and OCILy19, were a generous gift from Dr L Staudt
(National Institutes of Health) and were grown in Iscove’s
Modiﬁed Dulbecco’s Media (IMDM) with 20% human serum.
Everolimus was provided by Novartis Pharmaceuticals (Basel,
Switzerland) and was dissolved in 100% dimethyl sulfoxide to a
stock concentration of 100mM and stored at  801C. Annexin
V-ﬂuorescein isothiocyanate was obtained from BD Biosciences
(San Diego, CA, USA). For western blot analysis, 5 10
6 cells
were treated with 1, 10 and 50nM everolimus for 24h and
immunoblotting was performed as previously described.
12
Antibodies for phosphorylated mTOR (Ser 2448), S6 ribosomal
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www.nature.com/leuprotein (Ser 235/236) and 4E-BP1 (Thr37/46) were purchased
from Cell Signaling Technology (Danvers, MA, USA). For the
studies of cell proliferation, the cells were cultured in
96-well round-bottom microtiter plates (Costar, Cambridge,
MA, USA) at a density of 5 10
4 cells/well in the presence
of various concentration of everolimus. Before harvesting,
cells were pulsed with 1mCi tritiated thymidine (
3H-TdR,
Amersham, Piscataway, NJ, USA) for 18h. Incorporation levels
of
3H-TdR were determined using a Beckman scintillation
counter (GMI, Ramsey, MN, USA).
Cell survival was determined by annexin V/propidium iodide
(PI) staining and ﬂow cytometry. In all, 0.5 10
6 cells were
cultured with various concentrations of everolimus for 48h.
Cells were then stained using 1mg/ml annexin V-FITC, washed
once in annexin –V-binding buffer and stained with 0.5mg/ml PI,
and analyzed by ﬂow cytometry (FACSCalibur, Becton
Dickinson, Franklin Lakes, NJ, USA). Data analysis was
performed with FLOW JO software (Becton Dickinson).
Clinical trial patients and methods
A two-stage phase II study was conducted to assess the propor-
tion of patients with relapsed aggressive NHL who achieved a
partial response or better after treatment with single-agent
everolimus. The study was conducted through the Mayo Clinic
Cancer Center and Dana Farber Cancer Center, and was
approved by the respective Institutional Review Boards. Patients
were eligible if they had previously received therapy and had
relapsed or were refractory to their last treatment. There was
no limit on the number of previous therapies. Patients were
required to have failed or be ineligible for stem cell transplant.
The relapse was biopsy proven within 6 months before enroll-
ment. Additional eligibility criteria were age X18 years old,
measurable disease by computed tomography or magnetic
resonance imaging with at least one lesion 42cm diameter,
life expectancy of X3 months, Eastern Cooperative Oncology
Group performance status p2, absolute neutrophil count
X1000 10(6)/l, platelet count X75000 10(6)/l, hemoglobin
X8g per 100ml, serum creatinine p2x the upper limit of
normal (ULN), serum total bilirubin p2 ULN (or direct bilirubin
of o1.5 UNL) and aspartate aminotransferase o3 ULN
(p5 ULN, if liver involvement is present).
Patients received 10mg of everolimus orally in the fasting state
daily; 4 weeks were considered as one cycle. A complete blood
count (CBC) was performed weekly during the ﬁrst cycle and on
day 1 of each subsequent cycle. At the time of retreatment, the full
dose of everolimus was prescribed, if the platelet count was
X40000 10(6)/l, the absolute neutrophil count X1000 10(6)/l
and there were no grade 3 or 4 non-hematological toxicities (NCI
Common Toxicity Criteria version 3.0). Patients who did not meet
the retreatment criteria had the dose held until recovery, followed
by a stepwise dose modiﬁcation to 5mg daily, 5mg every other
day and 5mg every third day. Patients could receive white blood
cell growth factors, if neutropenia developed at physician’s
discretion. Erythropoietin treatment for anemia was permitted per
standard guidelines.
Patients were restaged for response after two and six
cycles, and every three cycles thereafter. Responses were
categorized using the International Workshop Criteria.
20
Patients who progressed or had unacceptable toxicity at any
time discontinued therapy. Patients with stable disease after six
cycles continued treatment at physician’s discretion. Patients
who had a complete remission on cycle 6 or later were to
receive two additional cycles and then could either discontinue
everolimus or continue at physician’s discretion. Patients with
partial response after six cycles continued until progression or
toxicity.
Statistical design
This phase II study used a modiﬁed two-stage Simon optimum
design
21 to assess the efﬁcacy and tolerability of everolimus in
patients with aggressive lymphomas, in which the modiﬁcation
is that accrual was not suspended for the stage I analysis. The
ORR was estimated by the number of responses divided by
the number of evaluable patients. A patient was considered
evaluable for response if he received at least one dose of
everolimus. A total of 37 evaluable patients were required to test
the null hypothesis that the true ORR for this regimen is at most
5% versus the alternative hypothesis that the true ORR is 20% or
greater. The study had 90% power, with a 9% type I error rate. A
95% binomial conﬁdence interval for the true ORR was
calculated. Because of promising early results, 40 additional
patients with aggressive lymphoma were accrued to this study to
provide access to everolimus and to better assess the response
rate and toxicity proﬁle of this regimen.
DR was deﬁned as the time from the date of documented
response to the date of disease progression. Time to progression
was deﬁned as the time from registration to the date of disease
progression. Patients who had not yet progressed were censored
at the date of their last evaluation. Time to discontinuation of
active treatment was deﬁned as the time from registration to the
date the patient discontinued treatment. Patients who were still
receiving treatment at the time of these analyses were censored
at the date of their last evaluation. Progression-free survival was
deﬁned as the time from registration to the date of disease
progression or death from any cause. Overall survival was
deﬁned as the time from registration to death from any cause.
The distributions of these time-to-event end points were
estimated using the Kaplan–Meier method.
22 Toxicity was
deﬁned as an adverse event classiﬁed as being possibly,
probably, or deﬁnitely related to study treatment.
Results
mTOR pathway is constitutively activated in aggressive
lymphoma
Cyclin D1, a cell cycle protein downstream of mTOR, is
overexpressed in nearly all cases of MCL. To provide further
rationale for using the mTOR inhibitor everolimus in MCL, we
evaluated mTOR activity in three mantle cell lines Jeko, Mino
and Granta by measuring the phosphorylation proﬁle of mTOR
itself and its immediately downstream substrates S6 ribosomal
protein (S6RP) and 4E-BP1 by western blot analysis using
antibodies directed against mTOR-speciﬁc phosphorylation
sites for each protein. As shown in Figure 1a, we found that
all the three mantle cell lines displayed a high expression of
phosphorylated forms of S6RP and 4E-BP1, as well as mTOR on
Ser2481. These data suggest that mTOR pathway is constitu-
tively activated in mantle lymphoma and provides a rational
target for therapeutic agents such as everolimus.
Everolimus attenuates phosphorylation of S6RP and
4E-BP1 in aggressive lymphoma
To conﬁrm that everolimus is actually acting on its intended
target in aggressive NHL, we examined the phosphorylation
status of the mTOR itself and its target proteins 4E-BP1 and S6RP
after treatment with everolimus. Jeko1 (MCL) and DHL6
(DLBCL) cells were cultured with 1, 10 and 50nM everolimus
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Leukemiafor 24h, and western blot analysis was performed using
phospho-speciﬁc antibodies to mTOR, S6 and 4E-BP1. Treat-
ment with everolimus resulted in the abrogation of S6RP
phosphorylation in a dose-dependent manner in both the cell
lines (Figure 1b). We also found that everolimus decreased the
levels of p-4E-BP1 in a dose-dependent manner in Jeko but not
DHL6. We found similar results in previous experiments with
rapamycin.
12 These results suggest that everolimus is indeed an
mTORC inhibitor in aggressive NHL cells.
Blockade of mTOR signaling with everolimus inhibits
the growth of aggressive lymphoma, with little effect
on apoptosis
Inhibition of mTOR is known to induce cell cycle arrest in tumor
cells. Jeko (MCL) and DHL6 (DLBCL) cells were treated with
various doses of everolimus for 48h, followed by an assay of
proliferation. Everolimus inhibited the proliferation of both
cell lines in a dose-dependent manner with B50% reduction
in proliferation at 50nm everolimus compared with controls
(Figure 2a). Further experiments were performed to assess the
effect of everolimus on lymphoma cell survival. The three MCL
lines Jeko, Mino and Granta were treated with various doses of
everolimus, and viability was assessed by ﬂow cytometry using
annexin/PI staining. Similar to our results with rapamycin,
12
we found little effect on survival which was less than 10%
inhibition of cell survival in all MCL cell lines, without evidence
of any dose-dependent effect (Figure 2b).
Patient characteristics and clinical outcomes
A total of 77 patients were enrolled from September 2005 to
September 2008. The patient characteristics and disease types
are summarized in Table 1. The ORR was 30% (23/77; 95%
conﬁdence interval (CI): 20–41%) with 20 partial response and
3 complete remission unconﬁrmed (Table 2). A total of 18
additional patients had stable disease and 29 patients progressed
by the ﬁrst assessment. Seven patients went off study before
being evaluated for objective status. These results met the study
design criteria for success at both the interim and ﬁnal analysis
time points. The ORR for DLBCL patients was 30% (14/47), 32%
(6/19) for MCL and 38% (3/8) for follicular lymphoma grade III.
None of the three patients with the other disease types (one case
of CLL that transformed to DLBCL, one patient with precursor
T-lymphoblastic lymphoma and one unspeciﬁed high-grade
B-cell NHL) responded to everolimus. Tumor responses
occurred relatively early, with a median time to response for
responders of 2.0 months (range, 1.5–8.7 months). A total
of 16 responses occurred after two cycles, 1 response after four
cycles, 5 responses after six cycles and 1 response after nine
Figure 2 (a) Dose-dependent inhibition of mantle cell proliferation
(Jeko) and diffuse large B-cell lymphoma cell proliferation (DHL6) with
the mTOR inhibitor everolimus. (b) Treatment of three MCL cell lines
with everolimus has little effect on cell survival.
Figure 1 (a) Immunoblots of proteins from three mantle cell MCL cell
lines demonstrating constitutive activation of mTOR and the down-
stream proteins S6RP and 4EBP1. (b) Everolimus is a potent inhibitor of
p-S6RP in both MCL (Jeko) and diffuse large B-cell lymphoma (DHL6)
cell lines. Everolimus has less effect on p-4EBP1 in Jeko and no effect
on DHL6.
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Leukemiacycles. The ORR in patients with a history of a stem cell
transplantation was 32% (8/25).
The median DR for the responders (complete remis-
sion unconﬁrmed/partial response) was 5.7 months (95% CI:
3.6–12.3 months) and ﬁve responders remained progression free
at 12 months. Overall, 69 patients have had disease progression
and 62 patients have died (Figure 3). A total of 50 patients died
from disease progression. Other causes of death included an
adverse event in four patients (one grade 5 cholecystitis unlikely
related to treatment, one grade 5 intra-abdominal hemorrhage
unrelated to treatment, one unspeciﬁed adverse event while
receiving subsequent treatment and one sepsis unrelated to
treatment), complications from bone marrow transplant (one
patient), graft verses host disease (one patient), unproven disease
progression (one patient), death in hospice (one patient) and
unknown cause (four patients). The median follow-up on living
patients was 24 months (range, 10–48). The median time to
progression for all patients was 3.4 months (95% CI: 2.1–4.2),
the median progression-free survival was 3.0 months (95%
CI: 2.1–3.9) and the median overall survival from study entry
was 8.1 months (95% CI: 5.3–12.5).
Safety and tolerability
When considering adverse events of any cause, 43 patients
(56%) experienced a grade 3 or higher hematologic adverse
event (35% grade 3 and 21% grade 4) and 41 patients (53%)
experienced a grade 3 or higher non-hematologic adverse event
(40% grade 3, 10% grade 4 and 3% grade 5). Focusing only on
adverse events at least possibly attributable to the study therapy
(Table 3), 42 patients (55%) experienced a grade 3 or higher
hematologic toxicity (35% grade 3 and 19% grade 4). Grade
3 or 4 anemia, neutropenia and thrombocytopenia occurred in
14, 18 and 38% of the patients, respectively. A total of 22
patients (29%) experienced a grade 3 or higher non-hematologic
toxicity (23% grade 3 and 5% grade 4). The most frequent non-
hematologic grade 3 or 4 toxicities were hyperglycemia (8%),
fatigue (8%) and mucositis (3%).
Overall, 52 patients (68%) had at least one grade 3/4 toxicity
at least possibly related to everolimus. Although most patients
experienced toxicity, as described in Table 3, the incidence of
most of these complications was low and they were manageable
with dose interruptions and dose reductions. Thrombocytopenia
was the cause of most dose reductions and was rapidly
Table 1 Patient characteristics (n¼77)
Characteristic Number (%)
Age, years
Median, range 70 (36, 92)





Lymphoma stage at study entry
1, 2 10 (13)






Precursor T-lymphoblastic leukemia/lymphoma 1 (1)
Unspeciﬁed high-grade B-cell lymphoma 1 (1)
Previous stem cell transplant 25 (32)
Presence of B symptoms 7 (9)
Number of previous therapy treatments
Median, range 3 (1, 15)
Type of previous therapy
Rituximab 74 (96)
Anthracycline 70 (91)
Abbreviations: DLBCL, diffuse large B-cell lymphoma; FL-III, follicular
lymphoma grade III; MCL, mantle cell lymphoma; TL, transformed
lymphoma.
Table 2 Response to everolimus by disease type
Disease type N ORR (95% CI) CR PR
Total 77 30% (20–41) 3 20
DLBCL 47 30% (17–45) 0 14
MCL 19 32% (13–57) 2 4
FL-III 8 38% (9–76) 1 2
Other 3 0 0 0
Abbreviations: CI, conﬁdence interval; CR, complete remission;
DLBCL, diffuse large B-cell lymphoma; FL-III, follicular lymphoma
grade III; MCL, mantle cell lymphoma; ORR, overall response rate;
PR, partial remission.
Figure 3 Time to progression (a) and overall survival (b) in 77 eligible
patients with relapsed aggressive NHL treated with single-agent
everolimus.
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Leukemiareversible with drug delays of typically 1 week. Three
patients experienced grade 3 respiratory tract infection. Two
additional patients had grade 3 pulmonary toxicityFone with
cough and the other with dyspnea, hypoxia and non-infectious
pneumonitis.
A total of 77 patients received a median of 2.0 months of
everolimus treatment (range, 1 day–45.3þ months). A total of
75 patients have discontinued treatment, with the most common
reasons being disease progression (51 patients), adverse events
(6 patients) and refusal (4 patients). The median time to
discontinuation of treatment was 2.0 months (95% CI: 1.9–2.9
months). Five patients remained on drug for at least 12 months,
four patients for X18 months and four patients for X24 months.
Of the 77 patients who received at least one dose of
everolimus, 7 did not complete cycle 1 and 7 additional
patients went off at the end of cycle 1, leaving 63 pts who
received 41 cycle. The median number of cycles at 10mg daily
was two (range, 1–12), with 87% (55/63) of patients receiving
10mg daily at cycle 2. Of the 55 patients who received more
than one cycle at the full dose level, 14 eventually required a
dose reduction. A total of 28 patients (36%) had dose reductions
(19 patients) or treatment delays (17 patients). The most
common causes of dose reductions were hematologic toxicity
(thrombocytopenia or neutropenia), stomatitis, edema and
rash. Treatment delays were due to hematologic toxicity
(thrombocytopenia and neutropenia) and infection.
Discussion
The PI3K pathway has been demonstrated to be constitutively
activated in the majority of B-cell lymphomas as manifested
by phosphorylation of S6K and 4E-BP1 (Figure 1).
12,23,24
Preclinical studies in cell lines and primary samples of aggres-
sive NHL have demonstrated that rapamycin or its analogs has a
signiﬁcant antiproliferative effect on these specimens but does
not substantially inhibit tumor cell survival.
12 In this study, we
again demonstrated that everolimus, the mTOR inhibitor used
in this clinical study, efﬁciently inhibits mTOR activity in
aggressive lymphoma in-vitro as shown by decreased cell
proliferation and inhibits levels of phosphorylation of the down-
stream targets S6RP and 4E-BP1. Other investigators have found
similar results.
25 Everolimus can also sensitize MCL and DLBCL
cell lines to a variety of cytotoxic agents, including doxorubicin
and bortezomib.
26 This preclinical data provided the rationale
to perform this large phase II study of single-agent everolimus.
Although the ORR result of 30% achieved with everolimus in
this trial is modest, it is indeed signiﬁcant for several reasons.
Firstly, the relapsed aggressive patient population is particularly
difﬁcult to treat because they are typically older adults, heavily
pretreated and have tumors with high kinetic activity. In this
study, the median age of the patients was 70 years and they had
received a median of three previous therapies. The aggressive
nature of the tumors in these patients is reﬂected in the
substantial number of patients (18%) that went off-study after
only one cycle. Thus, ﬁnding an ORR of 30% in this group is
meaningful and provides the rationale for further studies of
combinations. Secondly, the everolimus treatment in this study
was single agent providing clear proof-of-principle that the
responses were due to everolimus and that this class of agents
may play an important role in the treatment of NHL. The fact
that the ORR was 30% with a median DR for responders of
nearly 6 months ﬁts with the preclinical data in NHL that
suggested that inhibition of mTOR would produce responses.
Thirdly, oral everolimus therapy was convenient and tolerable
even for extended periods of time.
The everolimus results for relapsed DLBCL are similar to the
ORR and DR found with single-agent lenalidomide.
27 The 32%
ORR with everolimus in relapsed MCL is similar to the 40% that
we found in our previous trials of temsirolimus
13,14 and higher
than the 22% determined in the phase III trial.
15 In the ﬁrst trial
of lenalidomide for relapsed NHL, Wiernik et al.
27 found tumor
responses in 8 of 15 (53%) patients with MCL. These pilot
results, if conﬁrmed, suggest that both mTOR inhibitors and
immunodulatory agents are active in MCL.
Everolimus and other mTOR inhibitors are generally well
tolerated. The mTOR inhibitors as a class can produce apthous-
type mouth ulcers, hyperlipidemia, dysgeusia that can produce
mild weight loss, thrombocytopenia and fatigue. Most all of
these toxicities can be managed with dose interruption and dose
reduction after the toxicity resolves. In the case of hyperlipide-
mia, the addition of a statin drug is often required to maintain
mTOR inhibitor dose intensity, especially if the patient has an
antitumor response and will be on the drug for an extended
period of time. We observed an 1% incidence of grade 3
dyspnea, a rate similar to that found in other studies with
everolimus
28 or temsirolimus.
10,15 The most recent report of
Table 3 Grade 3 and 4 toxicity (adverse events considered at least
possibly related to everolimus) was observed in 68% (52/77) of
patients
Toxicity Grade Total (%)
34
General
Fatigue 6 0 6 (8)
Mouth sores (mucositis) 2 0 2 (3)
Anorexia 1 0 1 (1)
Fever 1 0 1 (1)
Dehydration 1 0 1 (1)
Hypersensitivity 0 1 1 (1)
Edema 1 0 1 (1)
Hematologic
Anemia 10 1 11 (14)
Neutropenia 12 2 14 (18)
Thrombocytopenia 17 12 29 (38)
Metabolic
Hyperglycemia 6 0 6 (8)
Hypertriglyceridemia 1 1 2 (3)
Hypercholesterolemia 1 0 1 (1)
Hyponatremia 1 0 1 (1)
Hypokalemia 0 1 1 (1)
Tumor lysis syndrome 1 0 1 (1)
Renal failure 0 1 1 (1)
Hepatic
Aspartate aminotransferase 1 0 1 (1)
Infection
Respiratory 3 0 3 (4)
Skin 2 0 2 (3)
Urinary tract 1 0 1 (1)
Perianal 1 0 1 (1)
Pulmonary
Cough 1 0 1 (1)
Hypoxia 1 0 1 (1)
Dyspnea 1 0 1 (1)
Pneumonitis 1 0 1 (1)
A total of 34 patients (44%) experienced at least one grade 3 toxicity
and 18 (23%) experienced at least one grade 4 toxicity.
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Leukemiaeverolimus used in relapsed neuroendocrine tumors had a 13%
incidence of pulmonary toxicity.
29
The promising activity of mTOR inhibition also has implica-
tions for adjuvant therapy in lymphoma. Armand et al.
30 found
that patients with NHL or Hodgkin’s lymphoma who underwent
graft verses host disease prophylaxis with sirolimus after reduced
intensity allogeneic stem cell transplantation had an improved
survival relative to patients who received prophylaxis with a
calcineurin inhibitor plus methotrexate. Trials are underway in
DLBCL to test whether adjuvant everolimus after standard
rituximab-based chemoimmunotherapy has induced a complete
remission can lower the risk of relapse.
The lack of response of many patients with relapsed
aggressive NHL to everolimus in this trial indicates that a
mechanism or mechanisms of resistance to mTORC1 inhibition
exists or develops in these tumor cells. We have demonstrated
that when NHL cells are treated with prototypical mTORC1
inhibitors such as rapamycin, although mTORC1 is blocked, the
cells activate Akt through mTORC2 signaling, thus providing an
escape mechanism.
12 This has led to a search for agents that will
overcome this resistance or be synergistic with mTORC1 inhi-
bitors. Sorafenib, a novel multikinase inhibitor that acts through
inhibition of Raf kinase and VEGF receptors, has synergistic
activity in vitro with rapamycin.
31 This provided the rationale
for a phase I/II ongoing trial of sorafenib and everolimus for
relapsed B-cell malignancies. Rapamycin also has demonstrated
synergy with the histone deacetylase inhibitor LBH589, and a
phase I trial of LBH589 and everolimus are ongoing at multiple
centers.
12 Understanding the mechanisms of resistance in
lymphoma cells when exposed to these targeted agents will
shed further light on the pathways important to the growth and
maintenance of malignant B cells and provide important leads
into new mTOR-based combinations for aggressive NHL.
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